Radiation oncologist/ Ass.Professor/ University Marburg 🇩🇪/ #Radonchttps://bsky.app/profile/gawish.bsky.socialhttps://bsky.app/profile/gawish.bsky.social/post/3lo7kv5osfc2rWhat a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy02 May 2025 19:32 +0000at://did:plc:daftf32dst3cyrzpcdwac6nb/app.bsky.feed.post/3lo7kv5osfc2rhttps://bsky.app/profile/gawish.bsky.social/post/3lntu7wjiqk2dIn the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing: ✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92) ✅ Median EFS: 51.8 months vs. 30.4 months No clear benefit seen in the hypopharynx subgroup #HNSCC #Radonc #Immunotherapy #CancerResearch28 Apr 2025 03:47 +0000at://did:plc:daftf32dst3cyrzpcdwac6nb/app.bsky.feed.post/3lntu7wjiqk2dhttps://bsky.app/profile/gawish.bsky.social/post/3likmem6gms2qdurvalumab plus tremelimumab with concurrent radiotherapy : 81% CR #radonc #GU https://aacrjournals.org/clincancerres/article-abstract/31/4/659/751741/Bladder-Preservation-with-Durvalumab-plus?redirectedFrom=fulltext19 Feb 2025 20:27 +0000at://did:plc:daftf32dst3cyrzpcdwac6nb/app.bsky.feed.post/3likmem6gms2qhttps://bsky.app/profile/gawish.bsky.social/post/3lfff7hlhls2t Nivolumab Improves DFS in High-Risk Head & Neck SCC The Phase 3 NIVOPOSTOP trial (680 patients) showed that adding nivolumab to standard post-op CRT significantly improved DFS in resected LA-SCCHN with high relapse risk. A trend toward better OS was observed, pending final analysis. https://www.prnewswire.com/news-releases/gortec-announces-new-trial-success-for-head-and-neck-cancer-treatment-302344120.html10 Jan 2025 14:20 +0000at://did:plc:daftf32dst3cyrzpcdwac6nb/app.bsky.feed.post/3lfff7hlhls2t